APGE
$69.21-1.88 (-2.64%)
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indicat...
Recent News
VR Adviser Adds Over 1 Million Savara Shares
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.
Wedbush Raises Price Target on Apogee Therapeutics (APGE)
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 3, Wedbush increased its price target on Apogee Therapeutics Inc. (NASDAQ:APGE) from $90 to $95. The firm maintained an Outperform rating on the stock, which yields 30% upside potential at the current level. Apogee […]
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.
Apogee Therapeutics Teases 52-Week Zumi Durability Data, Phase III Path at TD Cowen Conference
Apogee Therapeutics (NASDAQ:APGE) outlined a series of near- and mid-term clinical milestones at TD Cowen’s 46th Annual Healthcare Conference, with management emphasizing upcoming durability data for its lead atopic dermatitis (AD) candidate zumilokibart (“Zumi”), a Phase III start by year-end, and
Is Rising R&D Spend And New Equity Shelf Altering The Investment Case For Apogee Therapeutics (APGE)?
Apogee Therapeutics recently reported a higher full-year 2025 net loss of US$255.84 million and a wider basic loss per share, while also filing a US$287.29 million common stock shelf registration and advancing multiple antibody programs toward key 2026 data readouts. These moves highlight a company leaning heavily into research and development and future trial milestones while positioning itself to access fresh capital through equity markets. We’ll now examine how Apogee’s deepening R&D...